Gilead’s Voluntary Licensing Agreements for Remdesivir with 5 generic companies
Posted on13 May 2020
Tagsdrug licensing, gilead, global pharma licensing deal, licensing deal in pharma, mylan licensing deal, nonexclusive, Remdesivir
Comments0
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir.... Read More
Market Exclusivity Case Study: XIFAXAN (rifaximin)
Posted on07 May 2020
Comments0
Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, which is one of the largest specialty pharmaceutical companies in... Read More
FDA Grants Accelerated Approval to Capmatinib for NSCLC
Posted on07 May 2020
Comments0
The FDA granted accelerated approval to capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a... Read More
Aleor Dermaceuticals receives EIR from US FDA for Karakhadi formulation facility
Aleor Dermaceuticals Ltd. (Aleor), a 60:40 joint venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has received... Read More
Lupin introduces ‘Jan Kovid’ helpline for Mumbai citizens
Posted on07 May 2020
Comments0
Lupin has announced the launch of the ‘Jan Kovid’ Helpline (1800-572-6130) under the tagline ‘Mann Ka Swaasthya, Tann Ki Suraksha’ for the residents... Read More
Bausch + Lomb – Stada Arzneimittel – Xbrane Biopharma – licensing deal for Lucentis biosimilar
Bausch + Lomb announced an exclusive licensing agreement with Stada Arzneimittel and its development partner Xbrane Biopharma to develop and commercialize a... Read More
Valneva And Pfizer to Co-Develop and Commercialize Lyme Disease Vaccine, Vla15
Valneva SE, a specialty vaccine company, and Pfizer Inc. today announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate... Read More
Ipsen agreement with IRICoR & Université de Montréal to acquire exclusive license for discovery-stage oncology programme
Ipsen, a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, announced they... Read More